{
    "nctId": "NCT00316836",
    "briefTitle": "Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole",
    "officialTitle": "The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 554,
    "primaryOutcomeMeasure": "Changes in breast density measured by percent and area at 1 and 2 years",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast cancer\n* Completely resected disease\n* One intact, noncancerous breast with no prior breast surgery in that breast except breast biopsy\n\n  * Mammogram available taken within 12 months prior to enrollment that includes side- and top-down views of the intact, noncancerous breast\n* Estrogen receptor- and/or progesterone receptor-positive tumor\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Postmenopausal\n* Agrees to retrieve and digitize mammograms taken prior to registration (within 12 months prior to atudy entry) and at approximately 1 and 2 years post-registration to this study\n* Agrees to have an additional blood banking specimen drawn at the same time as pre-treatment specimens are drawn for parent protocol CAN-NCIC-MA27\n* Agrees to have blood sample taken at 12 months post-registration on this study\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 6 months since prior hormone replacement therapy, oral contraceptives, tamoxifen, raloxifene, other selective estrogen-receptor modulators, or gonadotropin releasing-hormone analogues before pre-registration mammogram",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}